The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
It’s been a busy weekend for those lawyers working in the pharmaceutical sector.
Drugs retail giant Alliance-Boots revealed late last week that it had received a friendly £9.7bn takeover approach from US private equity house Kohlberg Kravis Roberts (KKR) – another busy bee, given its mooted offer with the rest of the CVC-led consortium for J Sainsbury.
Allen & Overy (A&O) and Slaughter and May have been battling it out to be Alliance-Boots’ go-to firm ever since the Boots and Alliance-Unichem merger last year.
It’s one-nil to Slaughters, with the news that Alliance-Boots is turning to the firm for its KKR approach. And that’s one hell of an instruction. (see story)
Still, A&O shouldn’t feel too glum given that it picked up, together with Lovells, the other big pharma instruction of the last few days: Schering-Plough’s £7.5bn purchase of Dutch giant Akzo Nobel’s drugs division. (see story)